Cholesteryl ester transfer protein and hyperalphalipoproteinemia in Caucasianss⃞ Published, JLR Papers in Press, December 28, 2006.

It is unclear whether cholesteryl ester transfer protein (CETP) contributes to high density lipoprotein cholesterol (HDL-C) levels in hyperalphalipoproteinemia (HALP) in Caucasians. Moreover, even less is known about the effects of hereditary CETP deficiency in non-Japanese. We studied 95 unrelated Caucasian individuals with HALP. No correlations between CETP concentration or activity and HDL-C were identified. Screening for CETP gene defects led to the identification of heterozygosity for a novel splice site mutation in one individual. Twenty-five heterozygotes for this mutation showed reduced CETP concentration (−40%) and activity (−50%) and a 35% increase of HDL-C compared with family controls. The heterozygotes presented with an isolated high HDL-C, whereas the remaining subjects exhibited a typical high HDL-C/low-triglyceride phenotype. The increase of HDL-C in the CETP-deficient heterozygotes was primarily attributable to increased high density lipoprotein containing apolipoprotein A-I and A-II (LpAI:AII) levels, contrasting with an increase in both high density lipoprotein containing apolipoprotein A-I only and LpAI:AII in the other group. This study suggests the absence of a relationship between CETP and HDL-C levels in Caucasians with HALP. The data furthermore indicate that genetic CETP deficiency is rare among Caucasians and that this disorder presents with a phenotype that is different from that of subjects with HALP who have no mutation in the CETP gene.

[1]  H. Bloomfield,et al.  LpA-I, LpA-I:A-II HDL and CHD-risk: The Framingham Offspring Study and the Veterans Affairs HDL Intervention Trial. , 2006, Atherosclerosis.

[2]  Michael Miller,et al.  The two novel CETP mutations Gln87X and Gln165X in a compound heterozygous state are associated with marked hyperalphalipoproteinemia and absence of significant coronary artery disease , 2006, Journal of Molecular Medicine.

[3]  J. Jukema,et al.  Common variants of multiple genes that control reverse cholesterol transport together explain only a minor part of the variation of HDL cholesterol levels , 2006, Clinical genetics.

[4]  J Wouter Jukema,et al.  Functional interaction between -629C/A, -971G/A and -1337C/T polymorphisms in the CETP gene is a major determinant of promoter activity and plasma CETP concentration in the REGRESS Study. , 2005, Human molecular genetics.

[5]  M. Trip,et al.  Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. , 2005, The American journal of cardiology.

[6]  A. Evans,et al.  A Case-Control Study of Lipoprotein Particles in Two Populations at Contrasting Risk for Coronary Heart Disease , 2005 .

[7]  J. Kastelein,et al.  A review of CETP and its relation to atherosclerosis Published, JLR Papers in Press, September 1, 2004. DOI 10.1194/jlr.R400007-JLR200 , 2004, Journal of Lipid Research.

[8]  J. Jukema,et al.  CETP gene variation: relation to lipid parameters and cardiovascular risk , 2004, Current opinion in lipidology.

[9]  D. Rader,et al.  Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. , 2004, The New England journal of medicine.

[10]  E. Schaefer,et al.  Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency Published, JLR Papers in Press, December 1, 2003. DOI 10.1194/jlr.M300198-JLR200 , 2004, Journal of Lipid Research.

[11]  T. Sand,et al.  Raising High-Density Lipoprotein in Humans Through Inhibition of Cholesteryl Ester Transfer Protein: An Initial Multidose Study of Torcetrapib , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[12]  Elisabeth Naschberger,et al.  Phage-displayed recombinant single-chain antibody fragments with high affinity for cholesteryl ester transfer protein (CETP): cDNA cloning, characterization and CETP quantification , 2004, Clinical chemistry and laboratory medicine.

[13]  S. Yamashita,et al.  Molecular mechanisms of cholesteryl ester transfer protein deficiency in Japanese. , 2004, Journal of atherosclerosis and thrombosis.

[14]  A. Zwinderman,et al.  Haplotype analysis of the CETP gene: not TaqIB, but the closely linked -629C-->A polymorphism and a novel promoter variant are independently associated with CETP concentration. , 2003, Human molecular genetics.

[15]  S. Yamashita,et al.  Prevalence and phenotypic spectrum of cholesteryl ester transfer protein gene mutations in Japanese hyperalphalipoproteinemia. , 2003, Atherosclerosis.

[16]  W. Cromwell,et al.  Measurement issues related to lipoprotein heterogeneity. , 2002, The American journal of cardiology.

[17]  A. Zwinderman,et al.  Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in Humans: A Randomized Phase II Dose-Response Study , 2002, Circulation.

[18]  A. Algra,et al.  Effect of intensive lipid-lowering strategy on low-density lipoprotein particle size in patients with type 2 diabetes mellitus. , 2001, Atherosclerosis.

[19]  T. Arai,et al.  Particle size analysis of high density lipoproteins in patients with genetic cholesteryl ester transfer protein deficiency. , 2000, Clinica chimica acta; international journal of clinical chemistry.

[20]  S. Squazzo,et al.  Association of polymorphisms at the SR-BI gene locus with plasma lipid levels and body mass index in a white population. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[21]  J. Virtamo,et al.  Molecular Genetic Study of Finns With Hypoalphalipoproteinemia and Hyperalphalipoproteinemia A Novel Gly230Arg Mutation (LCATFin) of Lecithin:Cholesterol Acyltransferase (LCAT) Accounts for 5% of Cases With Very Low Serum HDL Cholesterol Levels , 1998 .

[22]  J. Virtamo,et al.  Molecular genetic study of Finns with hypoalphalipoproteinemia and hyperalphalipoproteinemia: a novel Gly230 Arg mutation (LCAT[Fin]) of lecithin:cholesterol acyltransferase (LCAT) accounts for 5% of cases with very low serum HDL cholesterol levels. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[23]  W C Breckenridge,et al.  Human plasma CETP deficiency: identification of a novel mutation in exon 9 of the CETP gene in a Caucasian subject from North America. , 1998, Journal of lipid research.

[24]  A. Rigotti,et al.  A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[25]  D. Arveiler,et al.  Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction. , 1995, The Journal of clinical investigation.

[26]  R. Lampert,et al.  Circadian Variation of Sustained Ventricular Tachycardia in Patients With Coronary Artery Disease and Implantable Cardioverter‐ Defibrillators , 1994, Circulation.

[27]  W. Sluiter,et al.  Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism , 1994, European journal of clinical investigation.

[28]  S. Yamashita,et al.  A missense mutation in the cholesteryl ester transfer protein gene with possible dominant effects on plasma high density lipoproteins. , 1993, The Journal of clinical investigation.

[29]  A. Evans,et al.  A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM Study. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[30]  J. Buring,et al.  Decreased HDL2 and HDL3 Cholesterol, Apo A‐I and Apo A‐II, and Increased Risk of Myocardial Infarction , 1992, Circulation.

[31]  J. Ordovás,et al.  Plasma apolipoprotein A-I, A-II, B, E and C-III containing particles in men with premature coronary artery disease. , 1991, Atherosclerosis.

[32]  W. Willett,et al.  A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. , 1991, The New England journal of medicine.

[33]  S. Yamashita,et al.  Characterization of plasma lipoproteins in patients heterozygous for human plasma cholesteryl ester transfer protein (CETP) deficiency: plasma CETP regulates high-density lipoprotein concentration and composition. , 1991, Metabolism: clinical and experimental.

[34]  A. von Eckardstein,et al.  Apolipoprotein C-III(Lys58----Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia. , 1991, The Journal of clinical investigation.

[35]  酒井 尚彦.  Detection of two species of low density lipoprotein particles in cholesteryl ester transfer protein deficiency , 1991 .

[36]  A. Tall,et al.  Familial cholesteryl ester transfer protein deficiency is associated with triglyceride-rich low density lipoproteins containing cholesteryl esters of probable intracellular origin. , 1991, Journal of lipid research.

[37]  A. Tall,et al.  Organization of the human cholesteryl ester transfer protein gene. , 1990, Biochemistry.

[38]  A. Tall,et al.  Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins , 1989, Nature.

[39]  J. Fruchart,et al.  Apolipoprotein A-I containing lipoproteins in coronary artery disease. , 1987, Atherosclerosis.

[40]  T. Mohandas,et al.  Assignment of the human gene for cholesteryl ester transfer protein to chromosome 16q12-16q21. , 1987, Genomics.

[41]  C. Fielding,et al.  Cloning and sequencing of human cholesteryl ester transfer protein cDNA , 1987, Nature.

[42]  W. Kohr,et al.  Isolation and specificity of a Mr 74,000 cholesteryl ester transfer protein from human plasma. , 1987, Proceedings of the National Academy of Sciences of the United States of America.